Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oncobiologics, inVentiv in Biosimilars Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Oncobiologics, inVentiv in Biosimilars Alliance

inVentiv to provide clinical development for Oncobiologic's pipeline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Oncobiologics, Inc. and inVentiv Health have entered a strategic partnership for the clinical development of Oncobiologic’s pipeline. The global partnership will initially focus on biosimilar assets, including generic versions of Humira, Rituxan, Avastin, Herceptin and Erbitux, and could be expanded to include innovative molecules. inVentiv will lead and execute clinical studies, provide bioanalytical support for trials, and may also contribute commercialization capabilities in select countries.
 
“After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets. inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch,” said Oncobiologics chief executive officer, Pankaj Mohan, Ph.D.
 
Ray Hill, president, inVentiv Health Clinical said, “We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium.  With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv’s broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics